173 related articles for article (PubMed ID: 17433840)
1. Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure.
Kum LC; Yip GW; Lee PW; Lam YY; Wu EB; Chan AK; Fung JW; Chan JY; Zhang Q; Kong SL; Yu CM
Int J Cardiol; 2008 Mar; 125(1):16-21. PubMed ID: 17433840
[TBL] [Abstract][Full Text] [Related]
2. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
Rector TS; Carson PE; Anand IS; McMurray JJ; Zile MR; McKelvie RS; Komajda M; Kuskowski M; Massie BM;
Circ Heart Fail; 2012 Mar; 5(2):217-25. PubMed ID: 22267751
[TBL] [Abstract][Full Text] [Related]
3. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
Ter Arkh; 2006; 78(8):14-20. PubMed ID: 17078211
[TBL] [Abstract][Full Text] [Related]
4. Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure.
Blanchet M; Sheppard R; Racine N; Ducharme A; Curnier D; Tardif JC; Sirois P; Lamoureux MC; De Champlain J; White M
Am Heart J; 2005 May; 149(5):938.e1-7. PubMed ID: 15894946
[TBL] [Abstract][Full Text] [Related]
5. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
Ter Arkh; 2006; 78(9):61-71. PubMed ID: 17076227
[TBL] [Abstract][Full Text] [Related]
6. Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.
Tao ZW; Huang YW; Xia Q; Xu QW
Chin Med J (Engl); 2005 Jan; 118(2):146-54. PubMed ID: 15667801
[TBL] [Abstract][Full Text] [Related]
7. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.
Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Nucl Med; 2003 Jun; 44(6):884-90. PubMed ID: 12791814
[TBL] [Abstract][Full Text] [Related]
8. Is addition of angiotensin receptor blockade superior to increasing ACE inhibitor dose in patients with heart failure?
Brack J; Sindone A; Funston R; Schneider H; Skiba M; Ueng KC; Krum H
Int J Cardiol; 2010 Mar; 139(3):309-12. PubMed ID: 19027970
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
10. Effects of increased dose of diuretics on symptoms, weight, 6-minute walk distance, and echocardiographic measurements of left ventricular systolic and diastolic function in 51 patients with symptomatic heart failure caused by reduced left ventricular ejection fraction treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Kumar A; Aronow WS; Vadnerkar A; Sivan K; Mittal S
Am J Ther; 2009; 16(1):5-7. PubMed ID: 19142162
[TBL] [Abstract][Full Text] [Related]
11. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.
Carson P; Massie BM; McKelvie R; McMurray J; Komajda M; Zile M; Ptaszynska A; Frangin G;
J Card Fail; 2005 Oct; 11(8):576-85. PubMed ID: 16230259
[TBL] [Abstract][Full Text] [Related]
12. Irbesartan in patients with heart failure and preserved ejection fraction.
Massie BM; Carson PE; McMurray JJ; Komajda M; McKelvie R; Zile MR; Anderson S; Donovan M; Iverson E; Staiger C; Ptaszynska A;
N Engl J Med; 2008 Dec; 359(23):2456-67. PubMed ID: 19001508
[TBL] [Abstract][Full Text] [Related]
13. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction.
Yip GW; Wang M; Wang T; Chan S; Fung JW; Yeung L; Yip T; Lau ST; Lau CP; Tang MO; Yu CM; Sanderson JE
Heart; 2008 May; 94(5):573-80. PubMed ID: 18208835
[TBL] [Abstract][Full Text] [Related]
14. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group.
Tonkon M; Awan N; Niazi I; Hanley P; Baruch L; Wolf RA; Block AJ
Int J Clin Pract; 2000; 54(1):11-4, 16-8. PubMed ID: 10750252
[TBL] [Abstract][Full Text] [Related]
15. Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch.
Benedetto U; Melina G; Refice S; di Bartolomeo R; Roscitano A; Angeloni E; Sinatra R
Ann Thorac Surg; 2010 Dec; 90(6):1899-903; discussion 1903. PubMed ID: 21095333
[TBL] [Abstract][Full Text] [Related]
16. Effects of combination of AT1-antagonist candesartan cilexetil and ACE-inhibitors in patients with congestive heart failure.
Gasanin E; Dragutinović I; Banković D; Mitrović V
Srp Arh Celok Lek; 2013; 141(1-2):29-34. PubMed ID: 23539907
[TBL] [Abstract][Full Text] [Related]
17. BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction.
Falcão LM; Pinto F; Ravara L; van Zwieten PA
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):121-9. PubMed ID: 15526247
[TBL] [Abstract][Full Text] [Related]
18. [Effects of combination therapy with angiotensin I-converting enzyme inhibitor and angiotensin 1 receptor antagonist on ventricular remodeling and expression of endothelial nitric oxide synthase].
Zhang RY; Huang YL; Sun YH
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(15):1053-6. PubMed ID: 16029550
[TBL] [Abstract][Full Text] [Related]
19. [Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].
Coronel F; Cigarrán S; García-Mena M; Herrero JA; Calvo N; Pérez-Flores I
Nefrologia; 2008; 28(1):56-60. PubMed ID: 18336132
[TBL] [Abstract][Full Text] [Related]
20. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
